Paul J.Bröckelmann

Dr. med., MD Paul J. Bröckelmann

Uniklinikum Köln

Innere Medizin I - Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, Internistische Intensivmedizin


Kerpener Straße 62
50935 Köln
+49 177 7446555


  1. Garcia-Marquez MA, …, Bröckelmann PJ* & Schlösser HA* Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma Leukemia doi: 10.1038/s41375-021-01421-z *equal contribution IF 11.5
  2. Bröckelmann PJ, et al. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol 2021 Jan 10;39(2):107-115I IF 44.5
  3. Borchmann P, …, Bröckelmann PJ, et al. PET-guided omission of radiotherapy in earlystage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021 Feb;22(2):223-234. IF 41.3
  4. Bröckelmann PJ, et al. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL): A Multicenter, Randomized German Hodgkin Study Group Phase 2 Trial JAMA Oncol 2020 Apr 30 IF 31.8
  5. Reinke S*, Bröckelmann PJ*, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 Blood 2020 Dec 17;136(25):2851-2863 *equal contribution IF 22.1
  6. Bröckelmann PJ et al. Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche J Clin Oncol 2020 Nov 10;38(32):3816-3818 IF 44.5 Bröckelmann PJ, et al. Outcomes of Patients with 3rd or Higher Relapsed Classical
  7. Hodgkin Lymphoma: Results from the German Hodgkin Study Group. Ann Oncol 2019 Mar 1;30(3):490-491 IF 32.9
  8. Bröckelmann PJ, et al. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials J Clin Oncol 2017 May 1;35(13):1444-1450 IF 44.5
  9. Bröckelmann PJ, et al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 2017 Jun 1;28(6):1352-1358 IF 32.9
  10. Sasse S*, Bröckelmann PJ*, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017 Jun 20;35(18):1999-2007 *equal contribution IF 44.5
zurück zur Übersicht
Corporate Partners - Individual Sponsors
Thu, 27th October 2022 to Sat, 29th October 2022
Annual meeting of the European MCL Network
more dates
Sun, 12th June 2022
The Czernecki Donnelly Prize 2022 was awarded to Lorenz Thurner
more news